• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[原发性乳腺癌中尿激酶型纤溶酶原激活物免疫组化测定的预后价值]

[Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers].

作者信息

Göhring U J, Scharl A, Thelen U, Ahr A, Titius B R

机构信息

Klinik und Poliklinik für Frauenheilkunde und Geburshilfe, Universität zu Köln.

出版信息

Pathologe. 1995 Nov;16(6):398-403. doi: 10.1007/s002920050120.

DOI:10.1007/s002920050120
PMID:8570558
Abstract

There is ample evidence that the protease urokinase plasminogen activator (uPA) plays a role in invasion and spread of tumours. Several publications suggest its biochemical measurement in tumour cytosols to be of prognostic significance in breast carcinomas. Our study set out to determine whether the immunohistochemical detection of uPA in formalin-fixed, paraffin-embedded primary breast cancer tissues is of prognostic relevance. We tested 269 surgical specimens of primary ductal infiltrating carcinoma immunohistochemically using a modified avidin-biotin method. Some 57% of carcinoma specimens yielded specific positive staining in tumour cells. Detection of uPA correlated to tumour grade (P = 0.04), and to the detected level of the proliferation marker PCNA (P = 0.002), but not to patients' age or menopausal status, tumour size, nodal or steroid receptor status (P > 0.05). At median 68 months' follow-up, 34% of patients had experienced tumour relapse and 28% had died from cancer. Clinical course was correlated significantly to tumour size, tumour grade, nodal and steroid hormone receptor status (P < 0.05). Immunohistochemical detection of uPA, however, could not be demonstrated to be of any prognostic significance with regard to relapse-free or overall survival (P > 0.05) in the total study group or in the N0 (n = 120) and N + (n = 144) subgroups, regardless of whether univariate or multivariate analysis was applied.

摘要

有充分证据表明,蛋白酶尿激酶型纤溶酶原激活剂(uPA)在肿瘤的侵袭和扩散中起作用。一些出版物表明,在肿瘤细胞溶胶中对其进行生化检测对乳腺癌具有预后意义。我们的研究旨在确定在福尔马林固定、石蜡包埋的原发性乳腺癌组织中进行uPA的免疫组化检测是否具有预后相关性。我们使用改良的抗生物素蛋白-生物素方法对269例原发性导管浸润癌手术标本进行了免疫组化检测。约57%的癌标本在肿瘤细胞中产生特异性阳性染色。uPA的检测与肿瘤分级(P = 0.04)以及增殖标志物PCNA的检测水平相关(P = 0.002),但与患者年龄、绝经状态、肿瘤大小、淋巴结或类固醇受体状态无关(P > 0.05)。在中位随访68个月时,34%的患者出现肿瘤复发,28%的患者死于癌症。临床病程与肿瘤大小、肿瘤分级、淋巴结和类固醇激素受体状态显著相关(P < 0.05)。然而,在整个研究组或N0(n = 120)和N +(n = 144)亚组中,无论采用单因素分析还是多因素分析,uPA的免疫组化检测在无复发生存或总生存方面均未显示出任何预后意义(P > 0.05)。

相似文献

1
[Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers].[原发性乳腺癌中尿激酶型纤溶酶原激活物免疫组化测定的预后价值]
Pathologe. 1995 Nov;16(6):398-403. doi: 10.1007/s002920050120.
2
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].[免疫组织化学检测受体、组织蛋白酶、肿瘤抑制蛋白和增殖标志物作为原发性乳腺癌预后指标的价值]
Geburtshilfe Frauenheilkd. 1996 Apr;56(4):177-83. doi: 10.1055/s-2007-1022256.
3
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.尿激酶型纤溶酶原激活剂(uPA)和纤溶酶原激活剂抑制剂(PAI-1)在原发性浸润性导管癌患者中的预后意义——一项7.5年的随访研究
Tumori. 2011 Jul-Aug;97(4):532-9. doi: 10.1177/030089161109700419.
4
Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.免疫组织化学检测组织蛋白酶D和尿激酶型纤溶酶原激活剂在原发性乳腺癌中的比较预后价值。
Anticancer Res. 1996 Mar-Apr;16(2):1011-8.
5
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.侵袭标志物PAI-1无论是对原发性乳腺癌还是首次复发后的患者,在长期随访后仍是一个强有力的预后因素。
Breast Cancer Res Treat. 1999 Mar;54(2):147-57. doi: 10.1023/a:1006118828278.
6
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.肿瘤相关纤维蛋白溶解:纤溶酶原激活剂uPA和tPA在人类乳腺癌中的预后相关性
Blood Coagul Fibrinolysis. 1990 Dec;1(6):695-702.
7
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.侵袭因子尿激酶型纤溶酶原激活剂和纤溶酶原激活剂抑制剂1在原发性乳腺癌个体化治疗决策中的临床相关性在联合使用时最为显著。
J Clin Oncol. 2002 Feb 15;20(4):1000-7. doi: 10.1200/JCO.2002.20.4.1000.
8
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.尿激酶、尿激酶受体和纤溶酶原激活物抑制剂-1的联合过表达与乳腺癌进展相关:正常、良性和恶性乳腺组织的免疫组织化学比较
Cancer. 1996 Mar 15;77(6):1079-88. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z.
9
Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.肿瘤基质是人类乳腺癌中主要表达尿激酶型纤溶酶原激活物(uPA)、尿激酶型纤溶酶原激活物受体(uPAR)和纤溶酶原激活物抑制剂-1(PAI-1)的组织:预后影响。
Histol Histopathol. 2009 Jul;24(7):869-77. doi: 10.14670/HH-24.869.
10
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.尿激酶型纤溶酶原激活剂及其抑制剂和受体在乳腺癌患者中的预后价值。
Clin Breast Cancer. 2002 Jun;3(2):138-46. doi: 10.3816/CBC.2002.n.018.

引用本文的文献

1
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.雌激素对稳定表达雌激素受体的MDA-MB-231人乳腺癌细胞中纤溶酶原-纤溶酶系统各成分的调节作用
Br J Cancer. 1998 Jul;78(1):88-95. doi: 10.1038/bjc.1998.447.
2
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.尿激酶型纤溶酶原激活物和纤溶酶原激活物抑制剂-1在原发性乳腺癌中的预后意义
Br J Cancer. 1998 Mar;77(6):932-40. doi: 10.1038/bjc.1998.154.